Circulation
JOURNAL OF THE AMERICAN HEART ASSOCIATION

Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With CETP Gene Polymorphisms

Reecha Sofat, Aroon D. Hingorani, Liam Smeeth, Steve E. Humphries, Philippa J. Talmud, Jackie Cooper, Tina Shah, Manjinder S. Sandhu, Sally L. Ricketts, S. Matthijs Boekholdt, Nicholas Wareham, Kay Tee Khaw, Meena Kumari, Mika Kivimaki, Michael Marmot, Folkert W. Asselbergs, Pim van der Harst, Robin P.F. Dullaart, Gerjan Navis, Dirk J. van Veldhuisen, Wiek H. Van Gilst, John F. Thompson, Pamela McCaskie, Lyle J. Palmer, Marcello Arca, Fabiana Quagliarini, Carlo Gaudio, François Cambien, Viviane Nicaud, Odette Poirer, Vilmundur Gudnason, Aaron Isaacs, Jacqueline C.M. Witteman, Cornelia M. van Duijn, Michael Pencina, Ramachandran S. Vasan, Ralph B. D'Agostino, Sr, Jose Ordovas, Tricia Y. Li, Sakari Kakko, Heikki Kauma, Markku J. Savolainen, Y. Antero Kesäniemi, Anton Sandhofer, Bernhard Paulweber, Jose V. Sorli, Akimoto Goto, Shinji Yokoyama, Kenji Okumura, Benjamin D. Horne, Chris Packard, Dilys Freeman, Ian Ford, Naveed Sattar, Valerie McCormack, Debbie A. Lawlor, Shah Ebrahim, George Davey Smith, John J.P. Kastelein, John Deanfield and Juan P. Casas

Circulation 2010;121;52-62; originally published online Dec 21, 2009;
DOI: 10.1161/CIRCULATIONAHA.109.865444
Circulation is published by the American Heart Association. 7272 Greenville Avenue, Dallas, TX 72514
 Print ISSN: 0009-7322. Online ISSN: 1524-4539

Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With *CETP* Gene Polymorphisms

Reecha Sofat, MRCP*; Aroon D. Hingorani, PhD, FRCP*; Liam Smeeth, MRCGP, PhD; Steve E. Humphries, PhD, MRCP, FRCPath; Philippa J. Talmud, PhD; Jackie Cooper, MSc; Tina Shah, PhD; Manjinder S. Sandhu, PhD; Sally L. Ricketts, PhD; S. Matthijs Boekholdt, MD, PhD; Nicholas Wareham, MBBS, FRCP; Kay Tee Khaw, MBBCh, FRCP; Meena Kumari, PhD; Mika Kivimaki, PhD; Michael Marmot, PhD, FRCP; Folkert W. Asselbergs, MD, PhD; Pim van der Harst, MD, PhD; Robin P.F. Dullaart, MD, PhD; Gerjan Navis, MD, PhD; Dirk J. van Veldhuisen, MD, PhD; Wiek H. Van Gilst, PhD; John F. Thompson, PhD; Pamela McCaskie, PhD; Lyle J. Palmer, PhD; Marcello Arca, MD; Fabiana Quagliarini, MSc; Carlo Gaudio, MD; François Cambien, MD; Viviane Nicaud, MA; Odette Poirer, PhD; Vilmundur Gudnason, MD, PhD; Aaron Isaacs, PhD; Jacqueline C.M. Witteman, PhD; Cornelia M. van Duijn, PhD; Michael Pencina, PhD; Ramachandran S. Vasan, MD; Ralph B. D'Agostino, Sr, PhD; Jose Ordovas, PhD; Tricia Y. Li, MSc; Sakari Kakko, MD, PhD; Heikki Kauma, MD, PhD; Markku J. Savolainen, MD, PhD; Y. Antero Kesäniemi, MD, PhD; Anton Sandhofer, MD; Bernhard Paulweber, MD; Jose V. Sorli, MD, PhD; Akimoto Goto, MD, PhD; Shinji Yokoyama, MD, PhD, FRCPC; Kenji Okumura, MD, PhD; Benjamin D. Horne, MPH, PhD; Chris Packard, DSc; Dilys Freeman, BSc, PhD; Ian Ford, PhD; Naveed Sattar, PhD, FRCPath; Valerie McCormack, PhD; Debbie A. Lawlor, PhD; Shah Ebrahim, DM, MSc, FFPHM; George Davey Smith, MD, DSc, FFPHM; John J.P. Kastelein, MD, PhD; John Deanfield, BA, BCh, MB, FRCP; Juan P. Casas, MD, PhD

Background—Cholesteryl ester transfer protein (CETP) inhibitors raise high-density lipoprotein (HDL) cholesterol, but torcetrapib, the first-in-class inhibitor tested in a large outcome trial, caused an unexpected blood pressure elevation and

Received March 17, 2009; accepted October 20, 2009.

From the Centre for Clinical Pharmacology, Department of Medicine (R.S., A.D.H., T.S.), Department of Epidemiology and Public Health (A.D.H., M. Kumari, M. Kivimaki, M.M., J.P.C.), and Centre for Cardiovascular Genetics (S.E.H., P.J.T., J.C.), University College London, London, United Kingdom; Department of Epidemiology and Population Health (L.S., V.M., S.E., J.P.C.), London School of Hygiene and Tropical Medicine, London, United Kingdom; Department of Public Health and Primary Care (M.S.S., S.L.R., S.M.B.), Strangeways Research Laboratory, University of Cambridge, Cambridge, United Kingdom; MRC Epidemiology Unit (N.W.), Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, United Kingdom; Department of Clinical Gerontology (K.T.K.), University of Cambridge, Addenbrooke's Hospital, Cambridge, United Kingdom; Departments of Cardiology, Endocrinology, and Nephrology (F.W.A., P.v.d.H., R.P.F.D., G.N., D.J.v.V., W.H.V.G.), University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; Helicos BioSciences (J.F.T.), Cambridge, Mass; Centre for Genetic Epidemiology and Biostatistics (P.M., L.J.P.), University of Western Australia, Perth, Australia; Dipartimento di Clinica e Terapia Medica (M.A., F.Q.) and Dipartimento Cuore e Grossi Vasi Attilio Reale (C.G.), La Sapienza Università di Roma, Rome, Italy; INSERM UMRS 937, Université Pierre et Marie Curie–Paris 6 (F.C., V.N.), Paris, France; INSERM UMRS 956, Université Pierre et Marie Curie–Paris 6 (O.P.), Paris, France; University of Iceland (V.G.), Reykjavik, Iceland; Department of Epidemiology and Biostatistics (A.I., J.C.M.W., C.M.v.D.), Erasmus MC, Rotterdam, the Netherlands; Boston University (M.P., R.S.V., R.B.D., J.O.), Department of Mathematics and School of Medicine, Boston, Mass; Department of Nutrition (F.W.A., T.Y.L.), Harvard School of Public Health, Boston, Mass; Institute of Clinical Medicine (S.K., H.K., M.J.S., Y.A.K.), Department of Internal Medicine, Clinical Research Center and Biocenter Oulu, University of Oulu and Oulu University Hospital, Oulu, Finland; Department of Internal Medicine I (A.S.), Medical University Innsbruck, Innsbruck, Austria; Department of Internal Medicine (B.P.), Clinical Division of General Internal Medicine, University of Innsbruck Austria/Department of Internal Medicine, Paracelsus Medical University, Salzburg, Austria; Preventive Medicine Department (J.V.S.), University of Valencia, Spain and CIBER Fisiopatologia de la Obesidad y Nutricion (ISCIII); Cardiovascular Division (A.G.), JA Aichi Bisai Hospital, Sobuecho, Inazawa, Japan; Biochemistry (S.Y.), Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; Cardiovascular Research Medicine (K.O.), Nagoya University School of Medicine, Nagoya, Japan; Cardiovascular Department (B.D.H.), Intermountain Medical Centre/Department of Biomedical Informatics, University of Utah, Murray, Utah; Glasgow Royal Infirmary (C.P., D.F.), Glasgow, United Kingdom; Robertson Centre for Biostatistics (I.F.) and Faculty of Medicine (N.S.), BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom; Lifestyle and Cancer Group (V.M.), International Agency for Research on Cancer, Lyon, France; MRC Centre of Causal Analyses in Translational Epidemiology (D.A.L., G.D.S.), Department of Social Medicine, University of Bristol, United Kingdom; Department of Vascular Medicine (J.J.P.K., S.M.B.), Academic Medical Centre, Meibergdreef, Amsterdam, the Netherlands; and Vascular Physiology Unit (J.D.), UCL Institute of Child Health, London, United Kingdom.

*Drs Sofat and Hingorani contributed equally to this article.

Guest Editor for this article was Mary Cushman, MD, MSc.

The online-only Data Supplement is available with this article at http://circ.ahajournals.org/cgi/content/full/CIRCULATIONAHA.109.865444/DC1.

Correspondence to Professor Aroon Hingorani, Department of Epidemiology and Public Health, University College London, 1-19 Torrington Place, London WC1E 6BT, United Kingdom (e-mail a.hingorani@ucl.ac.uk), or to Dr Juan P Casas, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom (e-mail Juan.Pablo-Casas@lshtm.ac.uk).

Circulation **is available at http://circ.ahajournals.org** **DOI: 10.1161/CIRCULATIONAHA.109.865444**

increased cardiovascular events. Whether the hypertensive effect resulted from CETP inhibition or an off-target action of torcetrapib has been debated. We hypothesized that common single-nucleotide polymorphisms in the *CETP* gene could help distinguish mechanism-based from off-target actions of CETP inhibitors to inform on the validity of CETP as a therapeutic target.

Methods and Results—We compared the effect of *CETP* single-nucleotide polymorphisms and torcetrapib treatment on lipid fractions, blood pressure, and electrolytes in up to 67 687 individuals from genetic studies and 17 911 from randomized trials. *CETP* single-nucleotide polymorphisms and torcetrapib treatment reduced CETP activity and had a directionally concordant effect on 8 lipid and lipoprotein traits (total, low-density lipoprotein, and HDL cholesterol; HDL2; HDL3; apolipoproteins A-I and B; and triglycerides), with the genetic effect on HDL cholesterol (0.13 mmol/L, 95% confidence interval [CI] 0.11 to 0.14 mmol/L) being consistent with that expected of a 10-mg dose of torcetrapib (0.13 mmol/L, 95% CI 0.10 to 0.15). In trials, 60 mg of torcetrapib elevated systolic and diastolic blood pressure by 4.47 mm Hg (95% CI 4.10 to 4.84 mm Hg) and 2.08 mm Hg (95% CI 1.84 to 2.31 mm Hg), respectively. However, the effect of *CETP* single-nucleotide polymorphisms on systolic blood pressure (0.16 mm Hg, 95% CI −0.28 to 0.60 mm Hg) and diastolic blood pressure (−0.04 mm Hg, 95% CI −0.36 to 0.28 mm Hg) was null and significantly different from that expected of 10 mg of torcetrapib.

Conclusions—Discordance in the effects of *CETP* single-nucleotide polymorphisms and torcetrapib treatment on blood pressure despite the concordant effects on lipids indicates the hypertensive action of torcetrapib is unlikely to be due to CETP inhibition or shared by chemically dissimilar CETP inhibitors. Genetic studies could find a place in drug-development programs as a new source of randomized evidence for drug-target validation in humans. **(*Circulation*. 2010;121:52-62.)**

Key Words: genetics ■ pharmacology ■ epidemiology ■ high-density lipoproteins

Higher concentrations of high-density lipoprotein (HDL) cholesterol are associated with a lower risk of coronary heart disease (CHD) independent of low-density lipoprotein (LDL) cholesterol.[1] HDL particles have antiatherogenic actions in vitro, and experimental elevation of HDL cholesterol concentration in some animal models attenuates atheroma formation.[2,3] Inhibitors of cholesteryl ester transfer protein (CETP), which mediates exchange of lipids between HDL particles and other lipoproteins, are a new class of drugs developed for their ability to raise HDL cholesterol. However, when the combination of a CETP inhibitor (torcetrapib) and a statin (atorvastatin) was compared with atorvastatin alone in the Investigation of Lipid Level Management to Understand Its Impact in Atherosclerotic Events (ILLUMINATE) trial,[4] the Data Safety Monitoring Board terminated the trial prematurely because of an unexpectedly higher rate of both cardiovascular and noncardiovascular events in the torcetrapib-treated patients.

Clinical Perspective on p 62

Whether the higher rate of cardiovascular events from torcetrapib treatment was a mechanism-based effect of CETP inhibition, which would be shared by other members of the same drug class, or an idiosyncratic (or off-target) action of the torcetrapib molecule is uncertain. It is important to distinguish between the two, because at least 2 other CETP inhibitors, anacetrapib and dalcetrapib, are in advanced stages of drug development.[5–7] Torcetrapib treatment has been associated with consistent and substantial elevations in blood pressure,[4,8–10] perhaps secondary to a mineralocorticoid-like effect, which could have contributed to the increased risk of cardiovascular events.[11] Although it has been proposed that the other CETP inhibitors do not share this blood pressure–elevating effect,[5,12] this is based on evidence from nonrandomized animal experiments and short-term dose-ranging studies in humans, both of which have limitations. Large, randomized outcome trials of anacetrapib or dalcetrapib would provide a definitive answer but could expose the trial participants to a potential hazard should the hypertensive effect be mechanism based rather than off target. On the other hand, the failure to further evaluate other members of this class in randomized trials could lead to the abandonment of a potentially valuable preventive therapy.

An alternative way of obtaining randomized evidence on the efficacy and safety of CETP inhibition in humans without the recruitment of new trial participants, prospective follow-up, or exposure to a drug is to study the effect of carriage of common alleles of the human *CETP* gene associated with reduced CETP levels and activity.[13] Genetic association studies are a type of natural randomized trial, because maternal and paternal alleles assort at random at conception.[14,15] In effect, a study of alleles of the *CETP* gene that reduce CETP activity is akin to a very long-term randomized intervention trial of a "clean" CETP inhibitor, free from the off-target effects of individual drug molecules. We therefore compared the effect of torcetrapib and carriage of common *CETP* alleles on lipids and lipoproteins, blood pressure, and other markers of cardiovascular risk in a large-scale, international, collaborative analysis to ascertain whether the increase in blood pressure seen in the clinical trials of torcetrapib was mechanism based or off target.

Methods

Search Strategy and Selection Criteria

Randomized Controlled Trials

Randomized controlled trials evaluating the effect of torcetrapib on markers of cardiovascular risk or clinical outcomes were identified from PubMed and EMBASE up to the end of November 2007 with the use of the US National Library of Medicine's Medical Subject Headings and the free-text terms "torcetrapib" or "CETP inhibitor" in combination with "randomized controlled trial." For inclusion in the main analyses, studies had to be randomized, parallel-design studies in adults that examined the effect of treatment with torcetrapib (alone or in combination) with a suitable comparator. Studies were included if they had been

published as full-length articles or letters in peer-reviewed journals in any language. Randomized studies were further subdivided into shorter dose-finding studies of <1 year's duration and longer clinical trials of >1 year's duration and analyzed separately.

Genetic Studies

PubMed and EMBASE were searched up to November 2007 for studies in humans evaluating any polymorphism in the *CETP* gene. The search included the Medical Subject Headings and free-text terms "cholesteryl ester transfer protein" or "CETP" in combination with "polymorphism*," "mutation*," "allele*," "gene*," "Taq1B," "−629C>A," or "I405V," with no limits or restrictions. We supplemented information from published studies with unpublished genetic data obtained through a large collaborative network of investigators that allowed access to information on a wider range of traits of interest, enabled more precise estimation of genetic effect sizes, and minimized the scope for reporting and publication bias. (For further details, see the online-only Data Supplement.)

Generation of Tabular Data

Two of the authors (A.D.H. and R.S.) extracted data, and disagreements were resolved by discussion with a third author (J.P.C.). For randomized controlled trials, information was extracted on treatment regimen and comparator, as well as pretreatment and posttreatment measures of a wide range of cardiovascular risk markers (see the online-only Data Supplement for further details). The relationship between torcetrapib dose and effect on these variables, if available, was also recorded from dose-ranging studies. For genetic studies, study-level information was either extracted from published studies by 2 authors or requested from principal investigators (see the online-only Data Supplement).

Statistical Analysis

Randomized Clinical Trials of Torcetrapib

The effect of torcetrapib on different lipid fractions, blood pressure, and other cardiovascular traits was assessed by calculation of the difference in the change in mean values between active and control arms. Study-specific estimates were weighted by the inverse of the variance and pooled by random-effects meta-analysis to generate summary estimates.

Genetic Studies

Primary analyses were based on the *CETP* gene variants commonly referred to as TaqI B (rs708272) and −629C>A (rs1800775), which were the most widely typed variants. The 2 are in linkage disequilibrium (r^2 measure of association 0.73 in individuals of European descent[16]; online-only Data Supplement Figure I), which allows information on the 2 variants to be treated jointly in a pooled analysis. Additional analyses involved the I405V variant (rs5882). For continuous outcomes, the mean difference and 95% confidence interval (CI) by genotype category were obtained from each study and then pooled with a random-effects model to obtain a summary mean difference and 95% CI. Individuals homozygous for the common TaqIB (or −629C) allele served as the reference group throughout, and this group was designated B1B1, with heterozygous individuals and individuals homozygous for either rare allele designated B1B2 and B2B2, respectively, to preserve the convention introduced in prior studies. For binary outcomes, results were expressed as an odds ratio and 95% CI. To assess the robustness of the findings, stratified analyses were conducted according to study-level characteristics. In a subset of studies, predefined stratified analysis of individual-level data was performed to investigate the effect of *CETP* genotype on HDL cholesterol by quartiles of systolic, diastolic, and pulse pressure and by LDL cholesterol quartile to gain insight into the potential for effect modification by blood pressure–lowering or cholesterol-lowering medications. Deviation from Hardy-Weinberg equilibrium was assessed in each study. Heterogeneity was assessed with a χ^2 test. The I^2 measure[17] and 95% CI were used to describe the extent of variability across studies. Additional information on the statistical analysis is provided in the online-only Data Supplement. All analyses were conducted with Stata 9.0 (StataCorp LP, College Station, Tex).



Figure 1. A through C, Relationship between torcetrapib dose and HDL cholesterol and HDL2 and HDL3 subfractions. *P* values refer to the results of a meta-regression, and N refers to the total number of individuals in the 3 dose-ranging studies that contributed to this analysis.

Consistency Between *CETP* Gene Effects and Equivalent Torcetrapib Dose

To determine the consistency of the observed effect of *CETP* genotype on cardiovascular traits with the expected effects for a comparable dose of torcetrapib, the shape of the dose–effect relationship for torcetrapib was evaluated from dose-ranging trials by use of the reported continuous outcomes HDL, HDL2, and HDL3, as well as apolipoprotein A-I (apoA-I) and apolipoprotein B (apoB). Despite careful searching, no quantitative information on the relationship between torcetrapib dose and blood pressure from these trials was available in a form that could be used in the analysis. Having confirmed a linear dose–response relationship for the available variables (Figures 1A through 1C), we used the summary effect

Table 1. Effect of Torcetrapib (60 mg) and *CETP* Genotype on Lipids and Lipoproteins

Comparison: Lipids and Lipoproteins	Randomized Controlled Trials, Torcetrapib 60 mg No. of Studies (Individuals)	Summary Mean Difference (95% CI)	*P*	Genetic Studies, B1B2 vs B1B1 No. of Studies (Individuals)	Summary Mean Difference (95% CI)	*P*	Genetic Studies, B2B2 vs B1B1 No. of Studies (Individuals)	Summary Mean Difference (95% CI)	*P*
HDL cholesterol, mmol/L	4 (17 911)	0.78 (0.68–0.87)	<0.001	30 (54 971)	0.06 (0.05–0.07)	<0.001	30 (34 432)	0.13 (0.11–0.14)	<0.001
ApoA1,* g/L	1 (15 067)	0.30 (0.30–0.31)	<0.001	11 (22 909)	0.03 (0.02–0.04)	<0.001	11 (14 739)	0.06 (0.05–0.08)	<0.001
Total cholesterol, mmol/L	4 (17 911)	0.18 (0.10–0.25)	<0.001	29 (54 135)	0.01 (−0.01–0.02)	0.48	29 (33 970)	0.05 (0.03–0.07)	<0.001
LDL cholesterol, mmol/L	4 (17 911)	−0.54 (−0.64–−0.43)	<0.001	27 (51 860)	−0.01 (−0.03–0.00)	0.07	27 (32 424)	−0.03 (−0.05–0.01)	<0.01
Triglycerides, mmol/L	4 (17 911)	−0.12 (−0.18–−0.07)	<0.001	28 (52 084)	−0.04 (−0.06–−0.02)	<0.001	28 (32 589)	−0.06 (−0.10–−0.02)	<0.01
ApoB,* g/L	1 (15 067)	−0.11 (−0.11–−0.10)	<0.001	11 (22 909)	−0.01 (−0.02–0.00)	0.05	11 (14 739)	−0.02 (−0.03–0.01)	<0.01
HDL2, mmol/L	NA	NA	NA	2 (3086)	0.02 (0.01–0.02)	0.001	2 (1856)	0.03 (0.01–0.04)	0.01
HDL3, mmol/L	NA	NA	NA	2 (3086)	0.04 (0.02–0.05)	<0.001	2 (1856)	0.06 (0.02–0.11)	0.01
Apo-AII, mg/L	NA	NA	NA	3 (8661)	0.28 (0.26–0.31)	<0.001	3 (5632)	0.29 (0.26–0.32)	<0.001

NA indicates not applicable.

Differences between continuous traits are for values reported at the end of the randomized trials unless otherwise indicated.

*Data obtained after 3 months.

of a 60-mg dose of torcetrapib on HDL cholesterol (the measure with the most data) from the meta-analysis of randomized trials and the summary effect of *CETP* genotype on HDL cholesterol from the meta-analysis of genetic studies (1) to express the effect of carriage of the B2 variant as a torcetrapib dose equivalent and (2) to estimate the effect of this dose of torcetrapib on blood pressure and other traits. A simulation model that incorporated the variance in the effect estimates of the genotype and drug effects was used to obtain the CIs (see online-only Data Supplement for details). The observed gene effect was compared with the effect of a comparable dose of torcetrapib by means of a *z* test.[18] More details are provided in the online-only Data Supplement.

Results

Randomized Controlled Trials of Torcetrapib

Dose–Response Relationship of Torcetrapib on HDL

Three studies (median size 40 participants, range 19 to 162 participants) with a mean study duration of 5.3 (standard deviation 3.1) weeks enabled the exploration of the effect of different doses of torcetrapib on HDL cholesterol and its subfractions (HDL2 and HDL3).[19–21] Over the dose range studied (10 to 240 mg daily), torcetrapib produced a linear, dose-dependent increase in HDL cholesterol ($P<0.001$ from meta-regression), HDL2 ($P=0.03$), and HDL3 ($P=0.003$), with no evidence of a threshold effect (Figures 1A through 1C).

Effect of Torcetrapib on Lipid Profile, Blood Pressure, and Biomarkers

Four randomized trials (range 752 to 15 067 participants) with a mean duration of 21 (standard deviation 6) months that involved 17 911 participants in aggregate with a mean age of 55.4 (standard deviation 6.9) years evaluated the effect of torcetrapib 60 mg daily (in combination with atorvastatin) versus atorvastatin alone and were included in the main analysis.[4,8–10] Torcetrapib 60 mg daily increased HDL cholesterol by 0.78 mmol/L (95% CI 0.68 to 0.87 mmol/L), apoA-I by 0.30 g/L (95% CI 0.30 to 0.31 g/L), and total cholesterol by 0.18 mmol/L (95% CI 0.10 to 0.25 mmol/L). The same dose reduced LDL cholesterol by 0.54 mmol/L (95% CI −0.64 to −0.43 mmol/L), triglycerides by 0.12 mmol/L (95% CI −0.18 to −0.07 mmol/L), and apoB by 0.11 g/L (95% CI −0.11 to −0.10 g/L; Table 1; Figure IIa in the online-only Data Supplement). A pooled analysis of all 17 911 participants from the 4 trials indicated that torcetrapib 60 mg daily led to a mean increase in systolic blood pressure of 4.47 mm Hg (95% CI 4.10 to 4.84 mm Hg) and an increase in diastolic blood pressure of 2.08 mm Hg (95% CI 1.84 to 2.31 mm Hg). In the ILLUMINATE trial, the elevation in blood pressure was accompanied by a decrease in plasma potassium, an increase in sodium, and an increase in aldosterone concentration[4] (Table 2). In 3 trials[4,9,10] that included 17 159 participants, there was no effect of torcetrapib on C-reactive protein concentration (online-only Data Supplement Table I).

Genetic Studies

Study Details and CETP *Polymorphisms Evaluated*

A total of 31 studies (online-only Data Supplement references S1 to S39) and 67 687 individuals a mean of 55.8 (standard deviation 9.6) years old contributed information on at least 1 continuous outcome. Twenty-three studies with 60 316 individuals provided previously unpublished data. Of the unpublished studies, 21 studies (50 908 individuals) provided data on the rs708272 (Taq1B) polymorphism, and 2 studies (8535 participants) provided data only on the rs1800775 (−629C>A) polymorphism. Where studies provided data on both −629C>A and Taq1B, the latter was used for the primary analysis. Seven studies (21 353 individuals) also provided data on the rs5882 (I405V) polymorphism (online-only Data Supplement references S8, S10, S15, S16, S18–S20, S22, S25, S32, and S33), and these results are provided in the online-only Data Supplement. Study details are provided in online-only Data Supplement Tables II and III, respectively.

Effect of CETP *Genotypes on CETP Concentration, CETP Activity, and Lipids*

Six studies in individuals of European ancestry (5340 participants) provided information on the effect of *CETP* genotype on CETP concentration (online-only Data Supplement references S7, S8, S15, S28, S30, and S31), and 2 studies (858 participants; online-only Data Supplement references S15

Table 2. Effect of Torcetrapib (60 mg) and *CETP* Genotype on Blood Pressure and Circulating and Urinary Electrolytes and Creatinine

Comparison	Randomized Controlled Trials, Torcetrapib 60 mg No. of Studies (Individuals)	Summary Mean Difference (95% CI)	*P*	Genetic Studies, B1B2 vs B1B1 No. of Studies (Individuals)	Summary Mean Difference/Odds Ratio (95% CI)	*P*	Genetic Studies, B2B2 vs B1B1 No. of Studies (Individuals)	Summary Mean Difference (95% CI)	*P*
Blood pressure, mm Hg									
Systolic	4 (17 911)	4.47 (4.10–4.84)	<0.001	22 (47 841)	−0.27 (−0.64–0.10)	0.15	22 (30 047)	0.16 (−0.28–0.60)	0.46
Diastolic	4 (17 911)	2.08 (1.84–2.31)	<0.001	22 (47 841)	−0.23 (−0.43–−0.04)	0.02	22 (30 047)	−0.04 (−0.36–0.28)	0.80
Pulse pressure	NA	NA	NA	7 (29 411)	0.03 (−0.29–0.35)	0.88	7 (18 574)	−0.13 (−1.16–0.91)	0.81
Electrolytes and creatinine									
Plasma potassium, mmol/L†	1 (15 067)	−0.14 (−0.15–−0.13)	<0.001	6 (13 760)	0.00 (−0.01–0.01)	0.98	6 (8678)	−0.01 (−0.03–0.01)	0.39
Plasma sodium, mmol/L†	1 (15 067)	0.61 (0.51–0.71)	<0.001	6 (13 583)	−0.06 (−0.19–0.07)	0.35	6 (8554)	0.03 (−0.18–0.18)	0.98
Plasma creatinine, μmol/L†	1 (15 067)	−1.15 (−1.15–−0.75)	<0.001	4 (12 756)	−0.39 (−1.42–0.64)	0.45	4 (7956)	0.31 (−0.72–1.35)	0.55
Plasma bicarbonate, mmol/L†	1 (15 067)	0.35 (0.24–0.46)	<0.001	NA	NA	NA	NA	NA	NA
Plasma chloride, mmol/L†	1 (15 067)	0.07 (−0.02–0.16)	0.14	NA	NA	NA	NA	NA	NA
Urinary potassium, mmol/L	NA	NA	NA	1 (1599)	−1.84 (−5.15–1.47)	0.27	1 (1092)	−0.90 (−4.68–2.88)	0.64
Urinary sodium, mmol/L	NA	NA	NA	1 (1599)	2.29 (−2.46–7.04)	0.34	1 (1092)	3.60 (−1.99–9.19)	0.2
Urinary creatinine, mg/L	NA	NA	NA	1 (1599)	−0.26 (−0.91–0.39)	0.43	1 (1092)	−0.02 (−0.77–0.73)	0.96

NA indicates not applicable.
*Data obtained after 3 months.
†Data from ILLUMINATE only.
Differences between continuous traits are at end of the randomized trials unless otherwise indicated.

and S18–S20) provided information on the effect on CETP activity. A further 5 studies (1867 participants) contributed data from individuals of Japanese origin (online-only Data Supplement Figure III and references S34 through S39). A graded effect of genotype on CETP concentration and activity was evident in both populations. People of European ancestry who were homozygous for the B2 allele had lower CETP concentrations (−0.47 μg/mL, 95% CI −0.67 to −0.26 μg/mL) and lower CETP activity (−17.00 nmol · mL^{-1} · h^{-1}, 95% CI −18.52 to −15.49 nmol · mL^{-1} · h^{-1}) than people homozygous for the B1 allele (online-only Data Supplement Figures IIIa and IIIb). In 31 studies with 67 687 participants, B2-homozygous individuals had higher concentrations of HDL cholesterol (0.13 mmol/L, 95% CI 0.11 to 0.14 mmol/L; Figure 2). The link between genotype and HDL cholesterol was consistent in analyses stratified by study size, sex, presence of CHD, and ancestry and across quartiles of LDL cholesterol, systolic and diastolic blood pressure, and pulse pressure (online-only Data Supplement Figures IIIc and IV). In addition, B2-homozygous individuals exhibited higher concentrations of total cholesterol (0.05 mmol/L, 95% CI 0.03 to 0.07 mmol/L) and apoA-I (0.06 g/L, 95% CI 0.05 to 0.08 g/L) and lower concentrations of LDL cholesterol (−0.03 mmol/L, 95% CI −0.05 to −0.01 mmol/L), triglycerides (−0.06 mmol/L, 95% CI −0.10 to −0.02 mmol/L), and apoB (0.02 g/L, 95% CI −0.03 to −0.01 g/L). In 2 studies, individuals homozygous for the B2 allele had higher circulating concentrations of both the larger HDL2 particles (0.03 mmol/L, 95% CI 0.01 to 0.04 mmol/L) and smaller HDL3 particles (0.06 mmol/L, 95% CI 0.02 to 0.11 mmol/L; Table 1). Heterozygous subjects exhibited lipid and lipoprotein concentrations approximately intermediate between those found in homozygous subjects, consistent with an additive effect of each copy of the variant allele (Table 1; per-allele data available on request). The effect of variant *CETP* alleles on lipid and lipoprotein profile thus reproduced the direction of effect of treatment with torcetrapib in clinical trials for 8 separate lipid and lipoprotein traits (Table 1; Figure 3A; online-only Data Supplement Figures 2a and 2b). Using a simulation model and assuming a linear dose–response relationship (Figure 1), we estimated that the effect on HDL in B2-homozygous individuals corresponded to a



Figure 2. Effect of *CETP* genotype on HDL cholesterol in individuals of European ancestry. The B1B1 genotype is used as the reference group. The numbers refer to the total number of individuals that contribute to the comparisons shown.



Figure 3. A, Effect of torcetrapib and *CETP* gene variants on 6 lipid traits evaluated in both genetic studies and randomized trials. B, Observed effects of the *CETP* gene and expected effects of a 5- and 10-mg dose of torcetrapib dose on HDL cholesterol.

dose of torcetrapib of 9.7 mg (95% CI 8.18 to 11.41 mg), and for heterozygous individuals, it corresponded to a dose of 4.5 mg (95% CI 3.71 to 5.38 mg), ie, to a torcetrapib dose of approximately 10 and 5 mg, respectively (Figure 3B).

Effect of *CETP* Genotypes on Blood Pressure and Electrolytes

Twenty-two studies (58 948 individuals) provided information on *CETP* genotypes and systolic and diastolic blood pressure, including previously unpublished information from 20 studies (54 936 individuals). *CETP* genotype had no effect on systolic and diastolic blood pressure; the mean differences in comparisons between homozygous subjects were 0.16 mm Hg (95% CI −0.28 to 0.60 mm Hg) and −0.04 mm Hg (95% CI −0.36 to 0.28 mm Hg) for systolic and diastolic blood pressure, respectively. Mean differences in systolic and diastolic blood pressure between heterozygous individuals (B1B2) and those homozygous for the B1 allele were −0.27 mm Hg (95% CI −0.64 to 0.10 mm Hg) and −0.23 mm Hg (95% CI −0.43 to −0.04 mm Hg), respectively (Figure 4A). The null findings were again consistent in analyses stratified by study size, sex, presence of preexisting CHD, ancestral origin, and allele types (Figures 4A and 4B; online-only Data Supplement Figures Va and Vb). The expected effect on blood pressure of a 10-mg daily dose of torcetrapib was estimated to be 0.72 mm Hg (95% CI 0.60 to 0.87 mm Hg) and 0.33 mm Hg (95% CI 0.27 to 0.41 mm Hg) for systolic and diastolic blood pressure, respectively, assuming a linear relationship between torcetrapib dose and blood pressure, and this was significantly different from the observed genetic effect on blood pressure (Figures 5A and 5B). Unlike torcetrapib treatment, *CETP* genotype was not associated with serum sodium, potassium, or creatinine concentration or with urinary sodium or potassium concentration (Table 2; Figures 5C and 5D). Individuals with variant CETP alleles were also no more likely to receive antihypertensive medications (odds ratio 0.98, 95% CI 0.80 to 1.21; online-only Data Supplement Table I).



Figure 4. Effect of *CETP* genotype on systolic (A) and diastolic (B) blood pressure in populations of European descent. Weighted mean difference is given, with the B1B1 genotype used as the reference genotype. The numbers refer to the total number of individuals that contribute to the comparisons shown.

Effect of *CETP* Genotypes on Variables Unrelated to CETP Inhibition

There was no link between *CETP* genotypes and variables unrelated to CETP function, including age, body mass index, or smoking habit (online-only Data Supplement Table I). There was also no consistent association with blood glucose or with C-reactive protein concentration, consistent with data from clinical trials of torcetrapib (online-only Data Supplement Table I).

Discussion

Main Findings and Interpretation

We found concordance in the effect of common variants in the *CETP* gene and pharmacological inhibition of CETP by torcetrapib on 8 continuous lipid and lipoprotein markers evaluated in both randomized trials and genetic studies (HDL cholesterol, HDL2, HDL3, LDL cholesterol, triglycerides, total cholesterol, apoA-I, and apoB). The only continuous traits for which the effect of genotype and drug were consistently discordant were systolic and diastolic blood pressure and the electrolytes sodium and potassium. This large-scale randomized evidence in humans supports the interpretation that the blood pressure–elevating effect of torcetrapib (and the connected effect on electrolytes) is mechanistically unrelated to CETP inhibition. The findings have important implications, specifically for the development of other CETP inhibitors and more generally for the potential use of genetic variants to inform drug development.

Other Sources of Evidence on the Same Question

Our interpretation that the hypertensive effect of torcetrapib is off target receives additional support from other lines of evidence. First, treatment with the CETP inhibitors anacetrapib and dalcetrapib has not been associated with blood pressure elevation, although the studies thus far have been relatively small in size and of short duration.[5,7] Second, torcetrapib (but not anacetrapib) has been reported to cause a blood pressure increase in several animal models,[12] including species that do not express CETP. Third, a recent study[22] indicated that torcetrapib treatment elevates aldosterone concentration, with corresponding effects on sodium and potassium concentration, and these electrolyte changes were not observed in a short-term dose-ranging study of anacetrapib.[7] These findings, from the separate lines of investigation, each with differing limitations and sources of error, provide reassurance that the hypertensive effect of torcetrapib is off target and therefore unlikely to be shared by other CETP inhibitors.

CETP Inhibition and Prevention of CHD

The higher blood pressure among individuals in the torcetrapib arm of the ILLUMINATE trial might explain the higher rate of cardiovascular events, but there may also be other explanations. CETP inhibition might interfere with reverse cholesterol transport and generate an HDL particle of abnormal size and function,[23] a mechanism-based adverse effect. Prior small mechanistic studies have suggested torcetrapib treatment increased the concentration of both large HDL2 and small HDL3 particles but that the effect on HDL2 was proportionately greater. However, this differential effect was only seen at a dose of torcetrapib 4 times as large as the dose used in the large-scale clinical trials.[19] Genetic data on the effect of *CETP* genotype on HDL subtype were limited, but in the present analysis, there was no clear evidence of a



Figure 5. A through D, Observed effect of the *CETP* gene and expected effects of a 5- and 10-mg dose of torcetrapib on systolic (A) and diastolic (B) blood pressure, serum potassium (C), and sodium levels (D).

differential effect of *CETP* genotype on HDL subclasses. Although we have focused here on the effect of CETP genotypes on lipids, lipoproteins, and blood pressure to make direct comparison of the effect of pharmacological CETP inhibition and carriage of CETP alleles, a recent meta-analysis of studies that included 27 196 coronary cases and 55 338 controls and a genome-wide analysis from the Women's Genome Health Study both provided support for the CETP variants studied here being protective against CHD events.[24,25] Although this protective effect has not been consistent across all studies,[26] there has been no consistent signal for an increase in CHD risk from carriage of these alleles.

Potential Limitations

Although the findings are robust, our interpretation requires consideration in light of certain theoretical and practical limitations of the genetic approach we have used. *CETP* alleles are of much smaller effect than the most widely studied dose of torcetrapib, so it might be argued that the failure to detect an association between genotype and a continuous marker such as blood pressure could have arisen because of inadequate power, or perhaps the effect on blood pressure requires a suprathreshold degree of CETP inhibition. We attempted to maximize power and minimize the potential for a type II error by establishing a large genetic collaboration that included a substantial amount of previously unpublished information. Blood pressure was an outcome that had been widely recorded in the studies included in the present analysis (22 studies and 59 948 individuals) but was not widely reported, and so the findings should not be prone to bias. Although the investigation of the effect of *CETP* polymorphism on blood pressure was not the primary aim of any of the studies included here, blood pressure measurement was performed with validated devices and widely accepted methods. The study was also sufficiently powered to detect a blood pressure signal of the size expected of a 5- to 10-mg dose of torcetrapib (see the online-only Data Supplement). Indeed, 3 of these studies (14 109 individuals) contributed to the recent whole-genome analysis of blood pressure loci that identified single-nucleotide polymorphisms (SNPs) that altered blood pressure by ≈1 mm Hg/0.5 mm Hg, close to the effect size being sought in the present analysis.[27,28] With the available sample size, we also detected an effect of *CETP* genotype on triglycerides that was similar in size to that which would have been expected for blood pressure were this effect mechanism

based (online-only Data Supplement Figure IIa). We also triangulated the findings from randomized controlled trials with the genetic data (ie, we compared the expected effect of a 5- and 10-mg dose of torcetrapib with the observed genetic effect) rather than focusing solely on statistical tests in the genetic associations. Taken together, these analyses suggest that the null findings in relation to blood pressure are neither biased nor explained by inadequate sample size. Although we were unable to exclude a hypothetical nonlinear (threshold) relationship between CETP inhibition by torcetrapib and blood pressure because none of the dose-ranging studies of torcetrapib reported quantitative data on the dose–response effect in a form that could be extracted for analysis, the effect of torcetrapib on all lipid and lipoprotein traits evaluated was linear over the dose range studied. We therefore made the assumption that this was also true for blood pressure.

The randomized allocation of alleles in genetic studies differs from the randomized drug intervention in a clinical trial in that assignment of genotype occurs at conception and produces an effect across a lifetime, rather than in mid to late adulthood, when most randomized controlled trials are conducted. It is conceivable, therefore, that an adverse effect of a common genetic variant on blood pressure from early life may have led to developmental compensation by other systems.[15] If this were the case, a null association of *CETP* genotype with blood pressure seen in genetic studies might lead to unreliable inference on the likely effect of modification of CETP activity by a drug. However, there was no evidence that such developmental compensation was operating in the case of any of the 8 lipid traits we studied, for which both the lifelong effect of the genetic exposure and the shorter-term effect of the drug were consistent.

Although the precise functional alleles at the *CETP* locus have yet to be identified with certainty, the −629C>A (rs1800775) and I405V (rs5885) alleles are either likely to be functional themselves or to be in sufficiently strong linkage disequilibrium with functional variant(s) so as to be valid tools for this type of analysis. The −629C>A variant has been shown to alter binding of Sp transcription factors.[29] The Taq1B allele (rs708272) is intronic and less likely to be functional itself, but it is in strong linkage disequilibrium with several promoter polymorphisms (including the −629C>A variant), and as the present analyses show, it exhibits very strong association with multiple lipid traits. It is important to be clear, however, that for the analyses we have conducted, it is not necessary for functional alleles to have been delineated precisely provided that an effect of the alleles studied on the traits of interest can be demonstrated robustly.[30] Although there are likely to be other variants in and around the *CETP* gene that are also associated with CETP activity and lipids, some because they are causal and some because they are simply associated with causal SNPs by linkage disequilibrium, the use of a single SNP in this region does not compromise the analysis, provided it can be demonstrated that it provides a reliable index of CETP activity and differences in the lipid traits of interest (which we have demonstrated), and on the assumption that the SNP is in linkage disequilibrium with a causal SNP rather than causal itself, that the main analyses are grouped according to subjects of similar ancestry to ensure that the linkage disequilibrium relationships are consistent across studies. Moreover, SNPs at the CETP locus, including rs1800775 (−629C>A) and rs708272 (Taq1B) studied here, have emerged as among the strongest associated signals with HDL cholesterol in recent genome-wide association studies[25,31–33] (online-only Data Supplement Figure I).

Wider Implications of This Work

We used the principle that allelic variants in a gene encoding a specific drug target can be used to model the mechanism-based effect of modifying the same target pharmacologically. In the present analysis, this was applied to help distinguish the mechanism-based from off-target actions of a drug molecule in advanced development. However, further research should now address whether this principle could be exploited at earlier phases in the drug-development pathway to help, for example, with the validation of a promising new target or to assemble a panel of biomarkers of efficacy to test in clinical trials. The directional concordance of the effect of *HMGCR* SNPs in genetic studies and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (statin) treatment on LDL cholesterol and CHD risk in clinical trials lends additional support to the potential utility of this approach. There is likely to be wide availability of genetic tools for this purpose, because the majority of drug targets are proteins, and regulatory genetic variants acting in *cis*, located within 100 kb of genes, appear to be a common feature of the human genome.[34]

Conclusions

In summary, a novel large-scale genetic approach has provided evidence that the hypertensive effect of torcetrapib is likely an off-target action. This provides reassurance that this particular adverse effect of torcetrapib is unlikely to be shared by other chemically dissimilar CETP inhibitors, but further drug development will be required to assess whether these other agents and the CETP inhibitor class of drugs in general are likely to be efficacious in the prevention of CHD events with an acceptable risk–benefit profile. Further research should investigate whether genetic studies could find use in drug-development programs as a new source of randomized evidence for drug-target validation in humans.

Sources of Funding

Dr Sofat is supported by a British Heart Foundation (Schillingford) clinical training fellowship (FS/07/011). Dr Hingorani holds a British Heart Foundation senior fellowship (FS 05/125). Dr Smeeth holds a Wellcome Trust senior research fellowship. Dr Humphries holds a British Heart Foundation Chair in Cardiovascular Genetics; he and Dr Talmud are supported by British Heart Foundation PG04/110/17827. Dr Marmot is supported by a Medical Research Council research professorship. Dr Lawlor is funded in part by a United Kingdom Department of Health career scientist award. Dr Deanfield holds the British Heart Foundation Vandervell Chair in Cardiology of the Young. The Whitehall II study has been supported by grants from the Medical Research Council; Economic and Social Research Council; British Heart Foundation; Health and Safety Executive; Department of Health; US National Heart, Lung, and Blood Institute (HL36310), National Institutes of Health: US National Institute on Aging (AG13196), National Institutes of Health; US Agency for Health Care Policy and Research (HS06516); and the John D and Catherine T MacArthur Foundation Research Networks

on Successful Midlife Development and Socio-economic Status and Health. Samples from the English Longitudinal Study of Ageing DNA Repository received support under a grant (AG1764406S1) awarded by the National Institute on Aging. The English Longitudinal Study of Ageing was developed by a team of researchers based at the National Centre for Social Research, University College London and the Institute of Fiscal Studies. The data were collected by the National Centre for Social Research. The developers and funders of the English Longitudinal Study of Ageing and the Archive do not bear any responsibility for the analyses or interpretations presented here. EPIC-Norfolk is supported by the Medical Research Council and Cancer Research UK. The British Women's Heart and Health Study is funded by the Department of Health Policy Research Programme and the British Heart Foundation. The UK Medical Research Council provide support for the MRC Centre where Drs Lawlor and Smith work. The views expressed in the publication are those of the authors and not necessarily those of any of the funding bodies.

Disclosures

Dr Hingorani is a member of the editorial board of the Drug and Therapeutics Bulletin, has provided nonremunerated advice to GlaxoSmithKline and London Genetics, and has received honoraria for speaking at educational meetings on cardiovascular risk that have been donated in whole or in part to charity. Dr Arca was on the Pfizer advisory board for torcetrapib.

References

1. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. *Lancet*. 2007;370:1829–1839.
2. Sugano M, Makino N, Sawada S, Otsuka S, Watanabe M, Okamoto H, Kamada M, Mizushima A. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. *J Biol Chem*. 1998;273:5033–5036.
3. Whitlock ME, Swenson TL, Ramakrishnan R, Leonard MT, Marcel YL, Milne RW, Tall AR. Monoclonal antibody inhibition of cholesteryl ester transfer protein activity in the rabbit: effects on lipoprotein composition and high density lipoprotein cholesteryl ester metabolism. *J Clin Invest*. 1989;84:129–137.
4. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B. Effects of torcetrapib in patients at high risk for coronary events. *N Engl J Med*. 2007;357:2109–2122.
5. Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, Cote J, Rosko K, Chavez-Eng C, Lutz R, Bloomfield DM, Gutierrez M, Doherty J, Bieberdorf F, Chodakewitz J, Gottesdiener KM, Wagner JA. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. *Lancet*. 2007;370:1907–1914.
6. Kuivenhoven JA, de Grooth GJ, Kawamura H, Klerkx AH, Wilhelm F, Trip MD, Kastelein JJ. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. *Am J Cardiol*. 2005;95:1085–1088.
7. Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW III, Sisk CM, Mitchel Y, Pasternak RC. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. *Am Heart J*. 2009;157:352–360,e352.
8. Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, Kastelein JJ. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. *Lancet*. 2007;370:153–160.
9. Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. *N Engl J Med*. 2007;356:1620–1630.
10. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM. Effect of torcetrapib on the progression of coronary atherosclerosis. *N Engl J Med*. 2007;356:1304–1316.
11. Neal B, MacMahon S. An overview of 37 randomised trials of blood pressure lowering agents among 270,000 individuals: World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. *Clin Exp Hypertens*. 1999;21:517–529.
12. Forrest MJ, Bloomfield D, Briscoe RJ, Brown PN, Cumiskey AM, Ehrhart J, Hershey JC, Keller WJ, Ma X, McPherson HE, Messina E, Peterson LB, Sharif-Rodriguez W, Siegl PK, Sinclair PJ, Sparrow CP, Stevenson AS, Sun SY, Tsai C, Vargas H, Walker M III, West SH, White V, Woltmann RF. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. *Br J Pharmacol*. 2008;154:1465–1473.
13. Boekholdt SM, Thompson JF. Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. *J Lipid Res*. 2003;44:1080–1093.
14. Hingorani A, Humphries S. Nature's randomised trials. *Lancet*. 2005;366:1906–1908.
15. Davey Smith G, Ebrahim S. "Mendelian randomization": can genetic epidemiology contribute to understanding environmental determinants of disease? *Int J Epidemiol*. 2003;32:1–22.
16. Thompson JF, Wood LS, Pickering EH, Dechairo B, Hyde CL. High-density genotyping and functional SNP localization in the CETP gene. *J Lipid Res*. 2007;48:434–443.
17. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327:557–560.
18. Bautista LE, Smeeth L, Hingorani AD, Casas JP. Estimation of bias in nongenetic observational studies using "mendelian triangulation." *Ann Epidemiol*. 2006;16:675–680.
19. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. *N Engl J Med*. 2004;350:1505–1515.
20. Davidson MH, McKenney JM, Shear CL, Revkin JH. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. *J Am Coll Cardiol*. 2006;48:1774–1781.
21. Clark RW, Sutfin TA, Ruggeri RB, Willauer AT, Sugarman ED, Magnus-Aryitey G, Cosgrove PG, Sand TM, Wester RT, Williams JA, Perlman ME, Bamberger MJ. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. *Arterioscler Thromb Vasc Biol*. 2004;24:490–497.
22. Vergeer M, Bots ML, van Leuven SI, Basart DC, Sijbrands EJ, Evans GW, Grobbee DE, Visseren FL, Stalenhoef AF, Stroes ES, Kastelein JJ. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. *Circulation*. 2008;118:2515–2522.
23. Tall AR. CETP inhibitors to increase HDL cholesterol levels. *N Engl J Med*. 2007;356:1364–1366.
24. Thompson A, Di Angelantonio E, Sarwar N, Erqou S, Saleheen D, Dullaart RP, Keavney B, Ye Z, Danesh J. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. *JAMA*. 2008;299:2777–2788.
25. Ridker PM, Pare G, Parker AN, Zee RYL, Miletich JP, Chasman DI. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study. *Circ Cardiovasc Genet*. 2009;2:26–33.
26. Anand SS, Xie C, Pare G, Montpetit A, Rangarajan S, McQueen MJ, Cordell HJ, Keavney B, Yusuf S, Hudson TJ, Engert JC; INTERHEART Investigators. Genetic variants associated with myocardial infarction risk factors in over 8000 individuals from five ethnic groups: the INTERHEART Genetics Study. *Circ Cardiovasc Genet*. 2009;2:16–25.
27. Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, Glazer NL, Morrison AC, Johnson AD, Aspelund T, Aulchenko Y, Lumley T, Kottgen A, Vasan RS, Rivadeneira F, Eiriksdottir G, Guo X, Arking DE, Mitchell GF, Mattace-Raso FU, Smith AV, Taylor K, Scharpf RB, Hwang SJ, Sijbrands EJ, Bis J, Harris TB, Ganesh SK, O'Donnell CJ, Hofman A, Rotter JI, Coresh J, Benjamin EJ, Uitterlinden AG, Heiss G, Fox CS, Witteman JC, Boerwinkle E, Wang TJ, Gudnason V, Larson MG, Chakravarti A, Psaty BM, van Duijn CM. Genome-wide association study of blood pressure and hypertension. *Nat Genet*. 2009;41:677–687.

28. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, Najjar SS, Zhao JH, Heath SC, Eyheramendy S, Papadakis K, Voight BF, Scott LJ, Zhang F, Farrall M, Tanaka T, Wallace C, Chambers JC, Khaw KT, Nilsson P, van der Harst P, Polidoro S, Grobbee DE, Onland-Moret NC, Bots ML, Wain LV, Elliott KS, Teumer A, Luan J, Lucas G, Kuusisto J, Burton PR, Hadley D, McArdle WL, Brown M, Dominiczak A, Newhouse SJ, Samani NJ, Webster J, Zeggini E, Beckmann JS, Bergmann S, Lim N, Song K, Vollenweider P, Waeber G, Waterworth DM, Yuan X, Groop L, Orho-Melander M, Allione A, Di Gregorio A, Guarrera S, Panico S, Ricceri F, Romanazzi V, Sacerdote C, Vineis P, Barroso I, Sandhu MS, Luben RN, Crawford GJ, Jousilahti P, Perola M, Boehnke M, Bonnycastle LL, Collins FS, Jackson AU, Mohlke KL, Stringham HM, Valle TT, Willer CJ, Bergman RN, Morken MA, Doring A, Gieger C, Illig T, Meitinger T, Org E, Pfeufer A, Wichmann HE, Kathiresan S, Marrugat J, O'Donnell CJ, Schwartz SM, Siscovick DS, Subirana I, Freimer NB, Hartikainen AL, McCarthy MI, O'Reilly PF, Peltonen L, Pouta A, de Jong PE, Snieder H, van Gilst WH, Clarke R, Goel A, Hamsten A, Peden JF, Seedorf U, Syvanen AC, Tognoni G, Lakatta EG, Sanna S, Scheet P, Schlessinger D, Scuteri A, Dorr M, Ernst F, Felix SB, Homuth G, Lorbeer R, Reffelmann T, Rettig R, Volker U, Galan P, Gut IG, Hercberg S, Lathrop GM, Zelenika D, Deloukas P, Soranzo N, Williams FM, Zhai G, Salomaa V, Laakso M, Elosua R, Forouhi NG, Volzke H, Uiterwaal CS, van der Schouw YT, Numans ME, Matullo G, Navis G, Berglund G, Bingham SA, Kooner JS, Connell JM, Bandinelli S, Ferrucci L, Watkins H, Spector TD, Tuomilehto J, Altshuler D, Strachan DP, Laan M, Meneton P, Wareham NJ, Uda M, Jarvelin MR, Mooser V, Melander O, Loos RJ, Elliott P, Abecasis GR, Caulfield M, Munroe PB. Genome-wide association study identifies eight loci associated with blood pressure. *Nat Genet*. 2009;41:666–676.
29. Dachet C, Poirier O, Cambien F, Chapman J, Rouis M. New functional promoter polymorphism, CETP/-629, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and high density lipoprotein cholesterol levels: role of Sp1/Sp3 in transcriptional regulation. *Arterioscler Thromb Vasc Biol*. 2000;20:507–515.
30. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. *Stat Med*. 2008;27:1133–1163.
31. Kathiresan S, Melander O, Guiducci C, Surti A, Burtt NP, Rieder MJ, Cooper GM, Roos C, Voight BF, Havulinna AS, Wahlstrand B, Hedner T, Corella D, Tai ES, Ordovas JM, Berglund G, Vartiainen E, Jousilahti P, Hedblad B, Taskinen MR, Newton-Cheh C, Salomaa V, Peltonen L, Groop L, Altshuler DM, Orho-Melander M. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. *Nat Genet*. 2008;40:189–197.
32. Kooner JS, Chambers JC, Aguilar-Salinas CA, Hinds DA, Hyde CL, Warnes GR, Gomez Perez FJ, Frazer KA, Elliott P, Scott J, Milos PM, Cox DR, Thompson JF. Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides. *Nat Genet*. 2008;40:149–151.
33. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, Heath SC, Timpson NJ, Najjar SS, Stringham HM, Strait J, Duren WL, Maschio A, Busonero F, Mulas A, Albai G, Swift AJ, Morken MA, Narisu N, Bennett D, Parish S, Shen H, Galan P, Meneton P, Hercberg S, Zelenika D, Chen WM, Li Y, Scott LJ, Scheet PA, Sundvall J, Watanabe RM, Nagaraja R, Ebrahim S, Lawlor DA, Ben-Shlomo Y, Davey-Smith G, Shuldiner AR, Collins R, Bergman RN, Uda M, Tuomilehto J, Cao A, Collins FS, Lakatta E, Lathrop GM, Boehnke M, Schlessinger D, Mohlke KL, Abecasis GR. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. *Nat Genet*. 2008;40:161–169.
34. Melzer D, Perry JR, Hernandez D, Corsi AM, Stevens K, Rafferty I, Lauretani F, Murray A, Gibbs JR, Paolisso G, Rafiq S, Simon-Sanchez J, Lango H, Scholz S, Weedon MN, Arepalli S, Rice N, Washecka N, Hurst A, Britton A, Henley W, van de Leemput J, Li R, Newman AB, Tranah G, Harris T, Panicker V, Dayan C, Bennett A, McCarthy MI, Ruokonen A, Jarvelin MR, Guralnik J, Bandinelli S, Frayling TM, Singleton A, Ferrucci L. A genome-wide association study identifies protein quantitative trait loci (pQTLs). *PLoS Genet.* 2008;4:e1000072.

CLINICAL PERSPECTIVE

The inverse relationship between high-density lipoprotein cholesterol and risk of coronary heart disease suggests that therapeutic elevation of high-density lipoprotein cholesterol may provide an effective means of prevention of coronary heart disease. Pharmacological inhibition of cholesteryl ester transfer protein (CETP) leads to elevation in high-density lipoprotein cholesterol, but torcetrapib (the first-in-class CETP inhibitor) increased the risk of cardiovascular events in the ILLUMINATE trial (Investigation of Lipid Level Management to Understand Its Impact in Atherosclerotic Events), which may have resulted from an unexpected blood pressure–elevating effect of this agent. We used common genetic polymorphisms in the *CETP* gene to distinguish whether the hypertensive action of torcetrapib was mechanism based or off target, because a genetic study of these variants can be considered to be a type of natural randomized trial of a "clean" low-dose CETP inhibitor with no off-target actions. Common *CETP* gene polymorphisms and torcetrapib treatment had concordant effects on 8 lipid and lipoprotein markers, including high-density lipoprotein cholesterol, but *CETP* gene variants had no effect on blood pressure. The blood pressure–elevating effect of torcetrapib appears to be an off-target action that is unlikely to be shared by chemically dissimilar CETP inhibitors. Genetic studies could be used in drug-development programs as a new source of randomized evidence for drug-target validation in humans.

Correction

In the article "Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With *CETP* Gene Polymorphisms" by Sofat et al, which appeared in the January 5/12, 2010 issue of the journal (*Circulation.* 2010;121;52–62), one affiliation for Folkert W. Asselbergs, MD, PhD was incorrect.

The incorrect portion of the affiliations on page 52 should now read, ". . . Department of Epidemiology and Biostatistics (A.I., J.C.M.W., C.M.v.D.), Erasmus MC, Rotterdam, the Netherlands; Boston University (M.P., R.S.V., R.B.D., J.O.), Department of Mathematics and School of Medicine, Boston, Mass; Department of Nutrition (F.W.A., T.Y.L.), Harvard School of Public Health, Boston, Mass; . . . "

The online version of the article has been corrected. The authors regret the error.

DOI: 10.1161/CIR.0b013e3181d55816

(*Circulation*. 2010;121:e216.)

***Circulation* is available at http://circ.ahajournals.org**

Supplemental material:

Supplemental Methods

Search strategy and selection criteria; Genetic studies

Reference lists of articles identified from the primary search were additionally scanned for relevant articles, including previous meta-analyses and systematic reviews. For inclusion, genetic studies had to have more than 500 participants, involve unrelated subjects and be published as full length articles or letters in a peer reviewed journal. Authors of published studies were contacted (on at least 3 occasions) to obtain additional information on *CETP* genotypes and variables of interest, where unreported. The collaborative group for the genetic analysis was assembled by direct contact with principal investigators of any study known to the authors that involved more than 500 individuals that had previously reported at least one genetic finding, in any area, in a peer reviewed journal.

Twenty two studies were identified from the search and the published meta-analysis and seven were either reported after the previously published meta-analysis, or were contacted independently of the search as these studies were known to have published on genetic associations in lipids. Where data were duplicated in two publications, clarity was sought from the author, and limited tabular data were requested on the complete cohort. If there was no response, the larger of the data sets reported were included. Four unpublished cohorts were included.

Data Extraction

Randomised trials: Information was extracted on treatment regimen and comparator, pre- and post-treatment concentration of HDL-, LDL- and total cholesterol, triglycerides, apolipoproteins A-I (apoA-I) apolipoprotein B (apo-B), C-reactive protein (CRP), sodium, potassium, chloride, and bicarbonate, aldosterone, plasma creatinine and estimated glomerular filtration rate, systolic and diastolic blood pressure.

Genetic Studies: Information was obtained on study design, total number of participants and the number of individuals by genotype category, gender, ethnic origin and presence or absence of CHD at baseline. In addition, summary information on the following variables was obtained (where available) for each *CETP*-genotype group: CETP concentration, CETP activity, HDL-, LDL-, and total cholesterol, triglycerides, apoA-I and apoA-II, apoB, HDL sub-fractions 2 and 3, systolic and diastolic

blood pressure, blood glucose, CRP, urinary and plasma sodium, potassium and creatinine, body mass index, smoking status, age and treatment with anti-hypertensive medications or statins.

Statistical Analysis

For continuous traits, median values were assumed to be equal to mean values. If the standard deviation (SD) was not reported this was calculated from the standard error (SE) by multiplying the this by the square root of the sample size or from the inter-quartile range by dividing the width of the inter-quartile range by 1.349. For dose ranging studies, the SD was imputed from the largest study if unavailable. Where logged values were provided, these were back transformed and geometric means were used as means. Where cholesterol and triglycerides were reported in mg/ dl, values were converted to mmol/l by multiplying by 0.02586 and 0.01129 respectively. Similarly where glucose was reported as mg/dl values were converted to mmol/l by multiplying by 0.055, and creatinine was converted to µmol/L by multiplying by 88. We estimated using a MAF of 0.48, a sample size of 14,147 individuals was required to be able to detect a difference of 0.5 mmHg SBP, with a power of 0.8 at a significance of 0.05 (calculated using online genetic power calculator "Quanto" (S40)).

Simulation of observed gene vs expected torcetrapib dose equivalent effects: Once a linear dose response was confirmed for available variables, the summary effect with most data from dose finding or randomized trials (60mg) on HDL-C was used for simulation studies. The effect of 60 mg torcetrapib on HDL was called βd1(with standard error sd1), and for other i traits, similarly β_{di}(with standard error s_{di}). The simulation model then incorporated the variance in the effect estimates of the genotype and drug effects. This was done as follows: Firstly, a random draw (x_{d1}) of the 60mg drug effect on HDL cholesterol was taken from a normal distribution N($\beta_{d1,}s_{d1}$) and of the effect on each other trait (random draw x_{di} from N(β_{di},s_{di}), and of the gene effect on HDL cholesterol (draw x_{g1} from N($\beta_{g1,}s_{g1}$). The gene effect (x_{g1}) was then expressed as a torcetrapib dose equivalent, calculated as $dose_g=60\ x_{g1}/x_{d1}$, from which the expected effect of this dose on trait *i* was estimated as $e_{gi}=x_{di}x_{g1}/x_{d1,}$. Random draws were repeated 100000 times, generating a distribution of $dose_g$ from which its mean, 2.5th and 97.5th percentiles were used to estimate the mean (95% confidence interval) for the gene-dose equivalent. Similarly the mean of the distribution of expected effects on trait *i* was estimated (m_e_{gi}) as well as its standard error (s_{egi}) as (97.5th-2.5th percentiles)/(2x1.96). The observed gene

effect on trait i (β_{gi}) was compared to the expected effect of a comparable dose of torcetrapib (m_e_{gi}) using a Z- test, $z=(\beta_{gi}-m\_e_{gi})/\sqrt{(s_{gi}^2+ s_{egi}^2)}$.

Consistency between the CETP gene effects and equivalent torcetrapib dose

The 95% confidence intervals for the expected effect of a dose of torcetrapib comparable to the effect of genotype were obtained by simulation. To incorporate the uncertainty in the effect estimates, one hundred thousand replications were generated of the point estimates and standard errors of the 60 mg dose of torcetrapib. The values of the 2.5 and 97.5 centiles of the simulated distribution were uses as the 95% confidence intervals. The simulation process was conducted separately for individuals homozygous for the B2 allele and then repeated for heterozygous individuals.

Supplemental Results

Seven studies with 21, 353 individuals homozygous for the rs5882 (I405V) allele also had higher concentrations of HDL cholesterol (0.04 mmol/L; 0.00, 0.09), although the effect is less marked than that of rs7082872 (Taq1B). Similarly there was no evidence of a link between the I405V variant and blood pressure.

Supplemental Tables:

Table S1: Effect of torcetrapib (60 mg) and *CETP* genotype on other continuous and demographic variables.

Differences between continuous traits are those reported at the end of the randomised trial end unless otherwise indicated. Differences in demographic variables for RCTs were those recorded at baseline. ** only ILLUMINATE contributed to analysis.

Comparison	RCTs, Torcetrapib 60 mg (Number of Individuals)	Summary Mean Difference/ Odds Ratio (95% CI)	P value	Genetic Studies, B1B2 vs B1B1, no of studies (Individuals)	Summary Mean Difference/ Odds Ratio (95%CI)	P Value	Genetic Studies, B2B2 vs B1B1, no of studies (Individuals)	Summary Mean Difference/ Odds Ratio (95%CI)	P Value
Continuous traits									
C-reactive protein (mg/L)	2 (17,007)	0.02 (-0.04, 0.08)	0.52	13 (34,826)	0.03 (-0.07, 0.13)	0.60	13 (22,049)	0.16 (0.04, 0.29)	0.01
Glucose (mmol/L)	NA	NA	NA	11 (32,608)	0.00 (-0.02, 0.02)	0.95	11 (20,497)	0.03 (0.00, 0.06)	0.09
Demographic amd other variables									
Age	4 (17,911)	-0.48 (-1.29, 0.33)	0.25	19 (43,950)	0.00 (-0.20, 0.21)	0.98	19 (27,583)	0.18 (0.00, 0.35)	0.05
BMI (kg/m^2)	4 (17,911)	-0.06 (-0.22, 0.1)	0.46	19 (40,212)	-0.07 (0.15, 0.02)	0.12	19 (25,249)	-0.01 (-0.12, 0.10)	0.85
Treatment with statin	4 (17,911)	All treated with Atorvastatin	All treated with Atorvastatin	7 (20,600)	1.02 (0.10, 10.74)	0.99	7 (13,005)	0.92 (0.09, 9.79)	0.95
Treatment anti-hypertensive medication	3 (2,844)	0.98 (0.07, 13.3)	0.99	7 (20,077)	0.99 (0.83,1.17)	0.87	10 (15,154)	0.98 (0.80, 1.21)	0.85
Hypertension at baseline	4 (17,911)	1.04 (0.05, 22.5)	0.99	NA	NA	NA	NA	NA	NA
Current/ former vs never smoked	NA	NA	NA	9 (23,420)	0.92 (0.82, 1.03)	0.16	9 (14,649)	0.90 (0.78,1.04)	0.15

Table S2. Studies contributing to the CETP analysis

Study	Year of publication	Country	Gender male (%)	Mean age (years)	Total sample (n)	Study Description	Baseline coronary heart disease (CHD)	HWE χ^2 for main genotype included	CETP SNP(s) typed
*Published studies with blood pressure, **studies that did not respond to data request									
REGRESS[S30*]	1998	Netherlands	100	56	807	Cases of CHD from RCT	CHD	0.33	rs708272
Corella D [S11**]	1999	Spain	45	36.6	514	Cross sectional	No CHD	1.18	rs708272
Rekyavik [S13**]	2000	Iceland	100	71	1,134	Prospective cohort study - cases of CHD only	CHD	4.45	rs708272
Brousseau M [S9**]	2002	United States	100	64	833	Cross Sectional	CHD	3.71	rs708272
Atherogene [S6**]	2003	Germany	75	64.4	1,211	Prospective cohort of CHD	CHD	1.98	rs1800775
CARE[S12*]	2004	Canada, United States	86	59.5	3,205	Cases from RCT	CHD	1.78	rs708272
PHS [S24 **]	2005	United States	100	58.4	768	Prospective cohort	Mixed Population	1.01	rs708272
Marschang P [S31**]	2006	Austria	56	64.3	983	Prospective Cohort	CHD	0.06	rs708272
*Studies with unpublished data on blood pressure, *unpubublished studies									
EARS[S16+]	1999	Estonia, Belgium, Denmark, Finland, Germany, Greece, Italy, Portugal, Spain, Switzerland, United Kingdom	100	23	794	Cross sectional	No CHD	0.00	rs708272, rs5882
OPERA[S18,S19,S20*]	2000	Finland	49	51.4	524	Prospective cohort	Mixed Population	0.02	rs708272, rs158477
Framingham Offspring[S29*]	2000	United States	48.4	51.3	2,916	Prospective cohort	Mixed Population	1.84	rs708272
Arca M[S4*]	2001	Italy	65.4	58.7	798	Case control, additional group of population controls	Mixed Population	0.88	rs708272
ECTIM[S10,S15,S22*]	2002	France, United Kingdom	78	55.5	2,540	Case control	Mixed Population	1.27	rs708272, rs5882, rs1800775, G-971A
NPHS[S26*]	2002	United Kingdom	100	55.9	2,589	Prospective Cohort	No CHD	3.4	rs708272
WOSCOPS[S14*]	2003	United Kingdom	100	57	1,604	RCT	Mixed Population	0.28	rs708272
ACCESS[S25*]	2005	United states	60	60.3	2,106	RCT	Mixed Population	0.01	72 SNPs incuding rs708282, rs5882, rs1800775
Sorli[S27*]	2006	Spain	31	45.5	549	Cross sectional	Mixed Population	0.99	rs708272
PREVEND[S8*]	2006	Netherlands	50.5	49.4	8,166	Prospective cohort	Mixed Population	1.56	rs708272, rs1800775, rs5882
SAPHIR[S28*]	2008	Austria	68	52.7	1,503	Prospective Cohort	No CHD	0.31	rs708272
Busselton[S1*]	2007	Australia	45	49	1,574	Cross sectional	Mixed Population	1.05	rs708272, rs1800775, rs12149545
CUDAS[S1*]	2007	Australia	50	53	1,109	Cross sectional	Mixed Population	0.01	rs708272, rs1800775, rs12149546
CUPID[S1*]	2007	Australia	87	50	556	Cohort of patients presenting for coronary catheters	CHD	0.12	rs708272, rs1800775, rs12149547
Intermountain[S17*]	2007	United States	69	56	9,371	Cohort of patients presenting for coronary catheters	Mixed Population	1.22	32 SNPs incuding rs708282, rs5882, rs1800775
Health Professionals Study[S23*]	2007	United States	100	60	2,193	Prospective cohort study	No CHD	0.945	rs708272
Nurses Health Study[S5*]	2007	United States	0	57.4	1,291	Prospective cohort study	No CHD	1.3	rs708272
Rotterdam[S33*]	2007	Netherlands	41	68.8	6,421	Prospective cohort study	Mixed Population	0.48	rs5882, rs1800775
British Womens' Heart and Health Study[S21**]	Unpblished	United Kingdom	0	68.9	3,570	Prospective cohort study	Mixed Population	2.58	rs708272
EPIC-Norfolk[S7**]	Unpublished	United Kingdom	63	65.3	2,114	Prospective cohort study	No CHD	2.2	rs1800775
Whitehall II[S3**]	Unpublished	United Kingdom	73	49.8	5,049	Prospective cohort study	Mixed Population	0.61	rs708272
ELSA [S2**]	Unpublished	United Kingdom	46	63.6	5,541	Prospective cohort study	Mixed Population	1.35	rs708272
Erasmus[S32 ++]	Unpublished	Netherlands	40.7	53.12	873	Prospective cohort study	Mixed Population	0.024	rs5882

Table S3. Traits included from studies evaluating *CETP* Taq1B and -629C>A genetic variant in European descent individuals ("0" for not included and "1" for included)

Study	HDL-C	LDL-C	Total Cholesterol	Triglycerides	HDL2	HDL3	ApoA1	ApoB	SBP	DBP	PP	Glucose	BMI	CRP	Electrolytes and renal measures	Use of antihypertensive medication	Smoking status	Use of Statin
REGRESS	1	1	1	1	0	0	0	0	1	1	0	0	1	0	0	1	1	1
Corella D	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Rekyavik	1	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Brousseau	1	1	1	1	1	1	1	1	0	0	0	0	1	0	0	0	0	0
Atherogene	1	1	1	1	0	0	1	1	0	0	0	0	0	0	0	0	0	0
CARE	1	1	1	1	0	0	0	0	1	1	0	0	1	0	0	0	0	0
PHS	1	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Marschang P	1	1	1	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0
EARS	1	1	1	1	0	0	1	1	1	1	0	1	1	1	0	1	1	0
OPERA	1	1	1	1	0	0	0	0	1	1	0	0	1	0	1	0	0	0
Framingham	1	1	1	1	1	1	1	1	1	1	0	1	1	0	0	0	0	0
Arca M	1	1	1	1	0	0	0	0	1	1	0	0	0	0	1	0	0	0
ECTIM	1	1	1	1	0	0	1	1	1	1	0	0	1	0	0	1	1	0
NPHS II	1	1	1	1	0	0	1	1	1	1	1	1	1	1	0	0	1	0
WOSCOPS	1	1	1	1	0	0	1	1	1	1	0	1	1	1	1	1	1	1
ACCESS	1	1	1	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0
Sorli	1	1	1	1	0	0	0	0	1	1	0	0	0	0	0	0	0	0
PREVEND	1	1	1	1	0	0	1	1	1	1	1	1	1	1	1	1	1	1
SAPHIR	1	1	1	1	0	0	1	1	1	1	0	1	1	1	1	1	1	0
Busselton	1	1	1	1	0	0	0	0	1	1	0	0	1	0	0	0	0	0
CUDAS	1	1	1	1	0	0	0	0	1	1	0	1	1	1	0	0	0	1
CUPID	1	1	1	1	0	0	0	0	1	1	0	1	1	1	0	0	0	1
Intermountain	1	1	1	1	0	0	0	0	1	1	1	1	1	1	1	1	1	1
Health Professionals Study	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Nurses Health Study	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BWHHS	1	1	1	1	0	0	0	0	1	1	1	1	1	1	1	1	1	1
EPIC	1	1	1	1	0	0	1	1	1	1	1	1	1	1	1	1	1	0
Rotterdam	1	0	1	0	0	0	0	0	1	1	0	0	0	0	1	0	0	0
Whitehall II	1	1	1	1	0	0	1	1	1	1	1	1	1	1	0	0	1	0
ELSA	1	1	1	1	0	0	0	0	1	1	1	1	0	1	0	1	1	0

Supplemental Figures and Figure Legends:

Figure S1 LD structure of the *CETP* gene. r^2 values are given from the ACCESS study. The main SNPs evaluated in this study were Taq1B (rs708272) and -629C>A (rs1800775) which are in LD (r^2=0.73). SNPs contributing to variance in HDL cholesterol identified from genome wide association scans are also shown (rs12596776, rs2217332, rs3764261, rs1800775, rs711752, rs1864163, rs7205804, s5880, rs5882, rs1800777, rs1566439). Data provided by J F Thompson, ACCESS study[16]

Figure S2a and S2b Standardised mean differences in lipid and lipoproteins between individuals homozygous for *CETP* variants in populations studies (a) and and those receiving torcetrpaib 60mg (b) daily as compared to placebo in clinical trials

Figures S3a-c Effect of *CETP* genotype on (a) CETP concentration, (b) CETP activity and (c) HDL cholesterol concentration. Forest plots indicate weighted mean difference and 95% confidence intervals. Results are stratified by ancestral origin, study size, and prevalent coronary heart disease, gender and polymorphism typed. (*the B1B1 genotype grouped is used as the reference group throughout)

Figure S4: Association between *CETP* genotype (B2B2 vs B1B1) and HDL-cholesterol level stratified by systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure (PP) and LDL-Cholesterol. Data from 6 studies, (12,983 individuals)

Figure S5a-b Effect of *CETP* genotype on (a) systolic and (b) diastolic blood pressure in populations of European descent only. Forest plots show weighted mean difference and 95% confidence intervals. Results are stratified by study size, prevalent coronary heart disease, gender, polymorphism typed, and strata of LDL cholesterol. (The B1B1 genotype is used as the reference group, see text for details)

Figure S1



Figure S2a



Figure S2b



Figure S3a



Figure S3b



Figure S3c



Figure S4



Figure S5a



Figure S5b



Supplementary References:

S1. McCaskie PA, Beilby JP, Chapman CM, et al. Cholesteryl ester transfer protein gene haplotypes, plasma high-density lipoprotein levels and the risk of coronary heart disease. *Hum Genet* 2007;121:401-11.

S2. Marmot M, Banks J, Blundell R, Lessoff C, Nazroo J. Health, wealth and lifestyles of the older population in England: THE 2002 ENGLISH LONGITUDINAL STUDY OF AGEING: Institute of Fiscal Studies; 2002.

S3. Marmot M, Brunner E. Cohort Profile: the Whitehall II study. *Int J Epidemiol* 2005;34:251-6.

S4. Arca M, Montali A, Ombres D, et al. Lack of association of the common TaqIB polymorphism in the cholesteryl ester transfer protein gene with angiographically assessed coronary atherosclerosis. Clin Genet 2001;60:374-80.

S5. Asselbergs FW, Pai JK, Rexrode KM, Hunter DJ, Rimm EB. Effects of lymphotoxin-alpha gene and galectin-2 gene polymorphisms on inflammatory biomarkers, cellular adhesion molecules and risk of coronary heart disease. *Clin Sci (Lond)* 2007;112:291-8.

S6. Blankenberg S, Rupprecht HJ, Bickel C, et al. Common genetic variation of the cholesteryl ester transfer protein gene strongly predicts future cardiovascular death in patients with coronary artery disease. *J Am Coll Cardiol* 2003;41:1983-9.

S7. Boekholdt SM, Kuivenhoven JA, Wareham NJ, et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study. *Circulation* 2004;110:1418-23.

S8. Borggreve SE, Hillege HL, Wolffenbuttel BH, et al. The effect of cholesteryl ester transfer protein -629C->A promoter polymorphism on high-density lipoprotein cholesterol is dependent on serum triglycerides. *J Clin Endocrinol Metab* 2005;90:4198-204.

S9. Brousseau ME, O'Connor JJ, Jr., Ordovas JM, et al. Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial. *Arterioscler Thromb Vasc Biol* 2002;22:1148-54.

S10. Corbex M, Poirier O, Fumeron F, et al. Extensive association analysis between the CETP gene and coronary heart disease phenotypes reveals several putative functional polymorphisms and gene-environment interaction. *Genet Epidemiol* 2000;19:64-80.

S11. Corella D, Saiz C, Guillen M, et al. Association of TaqIB polymorphism in the cholesteryl ester transfer protein gene with plasma lipid levels in a healthy Spanish population. *Atherosclerosis* 2000;152:367-76.

S12. de Grooth GJ, Zerba KE, Huang SP, et al. The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy. *J Am Coll Cardiol* 2004;43:854-7.

S13. Eiriksdottir G, Bolla MK, Thorsson B, Sigurdsson G, Humphries SE, Gudnason V. The -629C>A polymorphism in the CETP gene does not explain the association of TaqIB polymorphism with risk and age of myocardial infarction in Icelandic men. *Atherosclerosis* 2001;159:187-92.

S14. Freeman DJ, Samani NJ, Wilson V, et al. A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study. *Eur Heart J* 2003;24:1833-42.

S15. Fumeron F, Betoulle D, Luc G, et al. Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction. *J Clin Invest* 1995;96:1664-71.

S16. Gudnason V, Kakko S, Nicaud V, et al. Cholesteryl ester transfer protein gene effect on CETP activity and plasma high-density lipoprotein in European populations. The EARS Group. *Eur J Clin Invest* 1999;29:116-28.

S17. Horne BD, Camp NJ, Anderson JL, et al. Multiple less common genetic variants explain the association of the cholesteryl ester transfer protein gene with coronary artery disease. *J Am Coll Cardiol* 2007;49:2053-60.

S18. Kakko S, Tamminen M, Paivansalo M, et al. Cholesteryl ester transfer protein gene polymorphisms are associated with carotid atherosclerosis in men. *Eur J Clin Invest* 2000;30:18-25.

S19. Kakko S, Tamminen M, Paivansalo M, et al. Variation at the cholesteryl ester transfer protein gene in relation to plasma high density lipoproteins cholesterol levels and carotid intima-media thickness. *Eur J Clin Invest* 2001;31:593-602.

S20. Kauma H, Savolainen MJ, Heikkila R, et al. Sex difference in the regulation of plasma high density lipoprotein cholesterol by genetic and environmental factors. *Hum Genet* 1996;97:156-62.

S21. Lawlor DA, Day IN, Gaunt TR, et al. The association of the PON1 Q192R polymorphism with coronary heart disease: findings from the British Women's Heart and Health cohort study and a meta-analysis. *BMC Genet* 2004;5:17.

S22. Le Goff W, Guerin M, Nicaud V, et al. A novel cholesteryl ester transfer protein promoter polymorphism (-971G/A) associated with plasma high-density lipoprotein cholesterol levels. Interaction with the TaqIB and -629C/A polymorphisms. *Atherosclerosis* 2002;161:269-79.

S23. Li TY, Zhang C, Asselbergs FW, et al. Interaction between dietary fat intake and the cholesterol ester transfer protein TaqIB polymorphism in relation to HDL-cholesterol concentrations among US diabetic men. *Am J Clin Nutr* 2007;86:1524-9.

S24. Liu S, Schmitz C, Stampfer MJ, et al. A prospective study of TaqIB polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged men. *Atherosclerosis* 2002;161:469-74.

S25. Lloyd DB, Lira ME, Wood LS, et al. Cholesteryl ester transfer protein variants have differential stability but uniform inhibition by torcetrapib. *J Biol Chem* 2005;280:14918-22.

S26. Talmud PJ, Hawe E, Robertson K, Miller GJ, Miller NE, Humphries SE. Genetic and environmental determinants of plasma high density lipoprotein cholesterol and apolipoprotein AI concentrations in healthy middle-aged men. *Ann Hum Genet* 2002;66:111-24.

S27. Sorli JV, Corella D, Frances F, et al. The effect of the APOE polymorphism on HDL-C concentrations depends on the cholesterol ester transfer protein gene variation in a Southern European population. Clin Chim Acta 2006;366:196-203.

S28. Sandhofer A, Tatarczyk T, Laimer M, et al. The Taq1B-variant in the Cholesteryl Ester-Transfer Protein Gene and the Risk of Metabolic Syndrome. *Obesity* (Silver Spring) 2008.; Apr16(4):919-22

S29. Ordovas JM, Cupples LA, Corella D, et al. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. *Arterioscler Thromb Vasc Biol* 2000;20:1323-9.

S30. Kuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. *N Engl J Med* 1998;338:86-93.

S31. Marschang P, Sandhofer A, Ritsch A, Fiser I, Kvas E, Patsch JR. Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin. *J Intern Med* 2006;260:151-9.

S32. Isaacs A, Sayed-Tabatabaei FA, Aulchenko YS, et al. Heritabilities, apolipoprotein E, and effects of inbreeding on plasma lipids in a genetically isolated population: the Erasmus Rucphen Family Study. *Eur J Epidemiol* 2007;22:99-105.

S33. Isaacs A, Sayed-Tabatabaei FA, Hofman A, et al. The cholesteryl ester transfer protein I405V polymorphism is associated with increased high-density lipoprotein levels and decreased risk of myocardial infarction: the Rotterdam Study. *Eur J Cardiovasc Prev Rehabil* 2007;14:419-21.

S34. Arai H, Yamamoto A, Matsuzawa Y, et al. Polymorphisms in four genes related to triglyceride and HDL-cholesterol levels in the general Japanese population in 2000. *J Atheroscler Thromb* 2005;12:240-50.

S35. Goto A, Sasai K, Suzuki S, et al. Cholesteryl ester transfer protein and atherosclerosis in Japanese subjects: a study based on coronary angiography. *Atherosclerosis* 2001;159:153-63.

S36. Ikewaki K, Mabuchi H, Teramoto T, et al. Association of cholesteryl ester transfer protein activity and TaqIB polymorphism with lipoprotein variations in Japanese subjects. *Metabolism* 2003;52:1564-70.

S37. Kawasaki I, Tahara H, Emoto M, Shoji T, Nishizawa Y. Relationship between TaqIB cholesteryl ester transfer protein gene polymorphism and macrovascular complications in Japanese patients with type 2 diabetes. *Diabetes* 2002;51:871-4.

S38. Meguro S, Takei I, Murata M, et al. Cholesteryl ester transfer protein polymorphism associated with macroangiopathy in Japanese patients with type 2 diabetes. *Atherosclerosis* 2001;156:151-6.

S39. Okumura K, Matsui H, Kamiya H, Saburi Y, Hayashi K, Hayakawa T. Differential effect of two common polymorphisms in the cholesteryl ester transfer protein gene on low-density lipoprotein particle size. *Atherosclerosis* 2002;161:425-31.

S40. Gauderman WJ, Morrison JM. QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies, http://hydra.usc.edu/gxe, 2006